Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with…
- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures, thus affecting more than 3!-->…
Weiterlesen...
Weiterlesen...